clinical trial · NCT03691064
Post-Authorization Long-Term Safety Study of LUTATHERA
Advanced Accelerator Applications·—·active not recruiting·n = 1,014
Neuroendocrine TumorsLUTATHERA
brief summary
Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).
started
Nov 28, 2018
primary completion
Sep 30, 2027
completion
Sep 30, 2027
last updated
Dec 23, 2025
detailed description
To assess the incidence and nature of potential long-term safety outcomes in patients with unresectable or metastatic, well-differentiated, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours. Retrospective and prospective data will be used.
official title
International, Non-interventional, Post-Authorization Long-Term Safety Study of Lutathera, in Patients With Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol